Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Companies
Recent news which mentions Companies
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
30
31
Next >
Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
July 21, 2023
Tags
Companies
Biotechnology
Oddity Tech Ltd
From
CNBC.com News
Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know
July 20, 2023
Tags
Health care industry
Spin/offs
Goldman Sachs Group Inc
From
CNBC.com News
Kenvue earnings top estimates in J&J spinoff's first quarterly report since IPO
July 20, 2023
Tags
Business
US: News
Health & Science
From
CNBC.com News
Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge
July 20, 2023
Tags
Companies
Biotechnology
Earnings
From
CNBC.com News
Pfizer Group B strep vaccine for infants returns encouraging mid-stage trial results
July 19, 2023
Tags
Business
US: News
Health & Science
From
CNBC.com News
Johnson & Johnson sues Biden administration over Medicare drug price negotiations
July 18, 2023
Tags
Bristol/Myers Squibb Co
Health care industry
Biotech and Pharmaceuticals
From
CNBC.com News
Novartis stock jumps after drugmaker raises full-year guidance, launches $15 billion buyback
July 18, 2023
Tags
Roche Holding AG
Novartis AG
Business News
From
CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023
Tags
Alzheimer's disease
Biotech and Pharmaceuticals
Health care industry
From
CNBC.com News
UnitedHealth stock jumps after earnings top estimates despite rising medical costs
July 14, 2023
Tags
Health & Science
Pharmaceuticals
Business
From
CNBC.com News
Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion
July 14, 2023
Tags
Obesity
Biotechnology
Companies
From
CNBC.com News
Uninsured Americans pay high costs for an insulin Eli Lilly vowed to price at $25, Sen. Warren says
July 13, 2023
Tags
Sanofi SA
US: News
Business
From
CNBC.com News
Biden administration to provide free Covid vaccines to uninsured Americans this fall through end of 2024
July 13, 2023
Tags
Coronavirus
Companies
Politics
From
CNBC.com News
Biden administration asks Pfizer, Moderna and Novavax for 'reasonable' prices on updated Covid vaccines
July 13, 2023
Tags
Companies
Vaccinations
Politics
From
CNBC.com News
FDA approves first over-the-counter birth control pill
July 13, 2023
Tags
Contraception controversy
Business News
Social issues
From
CNBC.com News
Nvidia invests $50 million in biotech company Recursion for AI drug discovery
July 12, 2023
Tags
Biotechnology
Companies
Technology
From
CNBC.com News
Illumina hit with record fine for closing Grail deal without EU regulatory approval
July 12, 2023
Tags
Mergers and acquisitions
Companies
Biotechnology
From
CNBC.com News
EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs
July 11, 2023
Tags
Obesity
Biotechnology
Companies
From
CNBC.com News
Few patients continue weight loss drugs like Wegovy after a year — but health costs soar for all
July 11, 2023
Tags
Novo Nordisk A/S
Breaking news
Biotechnology
From
CNBC.com News
White House unveils plan to eliminate threat of fentanyl laced with xylazine
July 11, 2023
Tags
Companies
Politics
Biotechnology
From
CNBC.com News
Novavax stock spikes 20% after company snags $350 million from Canada for unused Covid shots
July 10, 2023
Tags
Health & Science
Pharmaceuticals
Pfizer Inc
From
CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags
Biotech and Pharmaceuticals
Alzheimer's disease
Health care industry
From
CNBC.com News
Moderna strikes deal to develop mRNA drugs in China
July 05, 2023
Tags
Novo Nordisk A/S
Companies
Biotechnology
From
CNBC.com News
People should stop taking Ozempic, Wegovy obesity drugs before surgery, doctors group says
June 30, 2023
Tags
Eli Lilly and Co
Pharmaceuticals
Health & Science
From
CNBC.com News
Ex-Pfizer employee charged with illegal trading based on unreleased Covid pill trial data
June 29, 2023
Tags
Business News
Corruption
Collusion
From
CNBC.com News
CDC recommends RSV vaccines from Pfizer, GSK for adults 60 and older
June 29, 2023
Tags
Health care industry
Immunizations
Biotech and Pharmaceuticals
From
CNBC.com News
Asian chip stocks rally after Micron's bullish forecast signals easing supply glut
June 29, 2023
Tags
Semiconductors
Micron Technology Inc
Asia Economy
From
CNBC.com News
As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge
June 28, 2023
Tags
Weight management
Business News
Novo Nordisk A/S
From
CNBC.com News
Regeneron shares fall after FDA rejects high-dose eye disease treatment
June 27, 2023
Tags
Business
Biotech and Pharmaceuticals
US: News
From
CNBC.com News
Saudi Aramco looks to China and India to prop up oil markets
June 26, 2023
Tickers
OIL
Tags
Energy Commodities
Oil
Economic events
From
CNBC.com News
Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says
June 26, 2023
Tags
Health care industry
Biotech and Pharmaceuticals
Business News
From
CNBC.com News
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
30
31
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.